生命科学资讯
生物技术与制药领域的最新动态
Veradermics lands $256M IPO for oral Rogaine
Midi Health raises $100M as it plans expansion into urgent care, research
Hims adds Grail's cancer test amid questions about widespread use
Novartis says generics to erode $4B from 2026 sales
陷入困境的诺和诺德考虑收购月度GLP-1药物以强化产品组合
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
FDA要求撤回安进公司Tavneos，公司表示不会撤药。
FDA seeks withdrawal of Amgen's Tavneos, company says it won't pull drug
英国卫生部预计在美英医药贸易协议中投入10亿英镑
UK’s health department expected to spend £1B in pharma trade deal with US
诺和诺德预计2026年销售额将下滑，引发抛售潮
Novo expects sales to fall in 2026, triggering selloff
'扭转泰坦尼克号'：即将到来的PBM改革将如何改变CMS
'Turning around the Titanic': How the incoming PBM reforms will transform CMS
健康科技并购背后的驱动力是什么
What's driving health tech M&A
中国初创企业AccurEdit融资7500万美元用于基因编辑疗法研发。
China startup AccurEdit raises $75M for gene editing therapies
第一三共终止ADC药物研发；葛兰素史克研发部门裁员。
Daiichi ends work on an ADC; Layoffs at GSK's R&D unit
Ultragenyx公布可能成为其基因疗法重新提交核心的数据。
Ultragenyx unwraps data that may be central to its gene therapy resubmission
辉瑞第四季度财报中因抗癌药物计提44亿美元减值准备
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
辉瑞源自Metsera的月度GLP-1药物在六个月内减重10.5%
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
阿斯利康狼疮药物Saphnelo预充笔版本收到完全回应函。
AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
Carbon Health申请破产，寻求出售或重组。
Carbon Health files for bankruptcy, seeking to sell or restructure
首批10种医保谈判药品价格已生效：老年人真的省钱了吗？
First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
新CagriSema数据显示优于司美格鲁肽的改善效果。
New CagriSema data show improvement over semaglutide